Researchers at Stanford have developed a new method for using bacterial lipoproteins as nanocarriers for small molecule drugs, opening the door to a novel class of biodegradable, protein-based drug delivery vehicles.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Stanford researchers have repurposed two existing drugs and created a combined nanoparticle formulation that provides both intraocular pressure management and neuroprotection for glaucoma therapy.
Researchers at Stanford have developed a nanoparticle-based platform to enhance activation of self-specific CD8+ T cells in the tumor microenvironment to fight cancer while minimizing toxic side effects.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Researchers in the Felsher Lab at Stanford University have developed PD-L1 antibody fragment-conjugated nanoparticles to improve upon existing cancer immunotherapies and extend the range of indications to solid tumors.
These dual-function nanoparticles improve selectivity of myeloid treatment via identification and reduction of tumor progression in a two-step process: initial accumulation in tumor microenvironments, followed by targeted delivery of a therapeutic payload.
Researchers at Stanford have developed reactive oxygen species (ROS) sensing nanoparticles (NP) that can amplify Raman fingerprint signals and detect ROS changes.
Researchers at Stanford have developed a targeted delivery system using carbon nanotubes to specifically deliver cardiovascular drugs to treat atherosclerosis. A feature of atherosclerotic plaque is the accumulation of apoptotic cells.
Stanford researchers at the Airan Lab have developed a new method for robust and spatiotemporally precise non-invasive neuromodulation that could transform both basic and clinical neuroscience.
Stanford chemists have developed a scalable synthetic process to create a new class of viscous, stable phospholipid bilayer vesicles with tunable properties.